212Pb-DOTAM-GRPR1 is under clinical development by Orano Med and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how 212Pb-DOTAM-GRPR1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

212Pb-DOTAM-GRPR1 overview

212Pb-DOTAM-GRPR1 is under development for the treatment of solid tumors including cervical cancer, metastatic castrate resistant prostate cancer (mCRPC), metastatic colorectal cancer, human epidermal growth factor receptor 2 negative breast cancer (HER2- breast cancer), non-small cell lung cancer and cutaneous melanoma. The therapeutic candidate comprises of radioactive element lead (212Pb) along with the metal chelator DOTAM and acts by targeting GRPR. It is developed based on targeted alpha therapy (TAT) approach.

Orano Med overview

Orano Med formerly AREVA Med, a subsidiary of Orano SA is a biotechnology company that develops innovative nuclear medicines to treat cancers. Its cancer pipeline products include 212Pb-TCMC-trastuzumab for treating intra-abdominal HER-2 expressing malignancy; 212Pb labeled peptide targeting neuroendocrine tumors (NETs); 212Pb labeled monoclonal antibodies against hematological malignancies; and 212Pb-conjugated anti-CD37 antibody to treat leukemia. Orano Med developed new processes for producing lead-212 (212Pb), a rare radioactive isotope used in Targeted Alpha Therapy (TAT), a novel and potential research approach to nuclear medicine that facilitates the recognition and extermination of cancer cells while minimizing the damage to the healthy cells in the proximity. The company has collaborations with cancer research centers, universities, and other biotechnology companies. Orano Med is headquartered in Houston, Texas, the US.

For a complete picture of 212Pb-DOTAM-GRPR1’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.